HealthDay News — Induced pluripotent stem cell (iPSC) vaccines prevent tumor growth in syngeneic murine cancer models in a prophylactic setting, according to a study published online February 15 in Cell Stem Cell.
Noting that it may be possible for iPSCs to be harnessed to elicit anti-tumor responses in cancer vaccines, Nigel G. Kooreman, MD, from the Stanford University School of Medicine in California, and colleagues conducted a proof-of-principle study for using irradiated iPSCs in autologous anti-tumor vaccines.
The researchers found that iPSC vaccines prevented tumor growth in syngeneic murine breast cancer, mesothelioma, and melanoma models in a prophylactic setting. The iPSC vaccine inhibited melanoma recurrence at the resection site as an adjuvant and reduced metastatic tumor load, which was correlated with fewer Th17 cells and increased CD11b+GR1hi myeloid cells. Adoptive transfer of T cells isolated from tumor-bearing mice treated with the vaccine inhibited growth of tumors in unvaccinated recipients.
“Our data suggest a generalizable strategy for multiple types of cancer that could prove highly valuable in clinical immunotherapy,” the authors write.